RxDoctor Payments Data

Kimi Prentice, APRN

Nurse Practitioner · Ewa Beach, HINPI 1467684480

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $56,000 of the $64,957 with a category attached, or 86.2%. Fresenius USA Marketing, Inc. accounts for 98.4% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2023 at $19,442 and has fallen 74.6% since, to $4,931 in 2025. Among nurse practitioner clinicians in HI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$64,957in general payments, 2019–2025

Across 93 payments — averaging $698.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Fresenius USA Marketing, Inc.$64K
  • Amgen$322
  • Novo Nordisk$242
  • Sanofi$123
  • Bayer$110
  • AstraZeneca$79
  • plus $181 from 4 others

What the payments were for

  • Consulting fees$4,0006%
  • Speaking & faculty fees$56,00086%
  • Travel & lodging$1,6323%
  • Food & beverage$3,3255%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$64,957 in reported general payments places this provider in the 95th percentile of 215 nurse practitioner providers in Hawaii.

See all nurse practitioner providers in Hawaii

Medicare billing

Part B allowed, 2024
$78,221
Medicare patients
147
Services billed
420

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide140$378,057
Sevelamer Carbonate125$20,884
LokelmaSodium Zirconium Cyclosilicate20$14,068
Calcium Acetate35$2,012
Calcitriol25$787
Losartan Potassium47$619
Labetalol Hcl22$525
Lisinopril26$380
Amlodipine Besylate50$372
Midodrine Hcl16$364
Metoprolol Succinate12$295
Lidocaine-PrilocaineLidocaine/Prilocaine16$278
Potassium Chloride12$233
Furosemide44$202

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$63,900$378,057140 claims
AstraZenecaLokelma$79$14,06820 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 215 nurse practitioner providers in Hawaii.

Other nurse practitioner in Ewa Beach

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →